Longeveron Inc
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Longeveron Inc's stock with a target price of $11.72, indicating strong growth potential.
Financial Health
Longeveron Inc shows moderate revenue and strong profit margins, with healthy cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LGVN
Future Growth Leaders
Get ahead of the curve with this carefully selected collection of companies positioned for exceptional growth. Our professional analysts have identified these potential market titans operating in dynamic, high-growth sectors before their explosive potential is fully recognized by the masses.
Published: June 18, 2025
Explore BasketExpert-Backed Future Stars
This collection features emerging companies that have earned strong backing from financial experts and analysts. These carefully selected stocks represent innovative businesses with exceptional growth potential, positioned to become the market leaders of tomorrow.
Published: June 18, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Pipeline Focus
The company’s valuation is closely tied to its pipeline and trial readouts, which can create significant upside if results are favourable, though outcomes are uncertain.
High Volatility Risk
Small‑cap biotech shares often move sharply on news and financings; investors should expect high volatility and potential dilution from future capital raises.
Partnership Potential
Strategic collaborations or licensing deals can de‑risk programmes and unlock value, but final deals depend on data and negotiating progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
